Bromopride

Bromopride is a selective, irreversible, competitive, and orally effective dopamine D2 receptor antagonist. Bromopride can pass through the blood-brain barrier, inhibit the vomiting center, and enhance gastrointestinal motility, exerting antiemetic and gastrointestinal motility effects. Bromopride antagonizes dopamine-mediated vomiting reflexes and promotes gastrointestinal smooth muscle contraction, and has no adverse effects on abdominal wall healing in rats with postoperative abdominal infection. Bromopride can be used for the study of digestive system diseases (such as gastric hypomotility, nausea and vomiting) [1][2].

Product Specifications

CAS Number

[4093-35-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Bromopride.html

Purity

99.53

Solubility

DMSO : 170 mg/mL (ultrasonic)

Smiles

O=C(NCCN(CC)CC)C1=CC(Br)=C(N)C=C1OC

Molecular Formula

C14H22BrN3O2

Molecular Weight

344.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Huebner EA, et al. Diltiazem Promotes Regenerative Axon Growth. Mol Neurobiol. 2019 Jun;56 (6) :3948-3957.|[2]Dunne CE, et al. Metabolism of bromopride in mouse, rat, rabbit, dog, monkey, and human hepatocytes. Drug Metab Pharmacokinet. 2013;28 (6) :453-61.|[3]Oliveira MV, et al. Effects of bromopride on abdominal wall healing with induced peritoneal sepsis after segmental colectomy and colonic anastomosis in rats. Acta Cir Bras. 2011 Dec;26 (6) :433-7.